Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18672876 | TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE | May 2024 | September 2024 | Allow | 3 | 0 | 0 | No | No |
| 18583696 | METHODS AND POLYMER COMPOSITIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERS | February 2024 | January 2025 | Abandon | 11 | 1 | 0 | No | No |
| 17969739 | HIGH GLYCEROL COMPOSITION COMPRISING BLENDS OF ALKYL ISETHIONATE AND ALKYL TAURATE | October 2022 | October 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17907640 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | September 2022 | May 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17506269 | COMPOSITION COMPRISING ANTIMICROBIAL METAL IONS AND A QUATERNARY CATIONIC SURFACTANT | October 2021 | February 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17331543 | HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE | May 2021 | December 2024 | Abandon | 42 | 1 | 0 | No | No |
| 16965077 | HYDROPHILIC/HYDROPHOBIC PHARMACEUTICAL COMPOSITION AND METHOD OF ITS PRODUCTION AND USE | July 2020 | September 2024 | Allow | 50 | 2 | 1 | Yes | Yes |
| 16956237 | BCA CONTROL OF STB | June 2020 | September 2024 | Allow | 51 | 2 | 1 | No | No |
| 16620382 | SKIN CARE FORMULATIONS AND SKIN CANCER TREATMENT | December 2019 | May 2024 | Allow | 53 | 4 | 1 | Yes | No |
| 16398147 | Concentrated Liquid Compositions of Urease Inhibitors for Nitrogen Sources | April 2019 | December 2021 | Allow | 31 | 6 | 1 | Yes | No |
| 16325169 | MAGNETICALLY IMMOBILIZED BIOCIDAL ENZYMES AND BIOCIDAL CHEMICALS | February 2019 | June 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 15936574 | ANTIMICROBIAL COLLOIDAL SILVER PRODUCTS AND METHOD OF MAKING SAME | March 2018 | September 2019 | Allow | 18 | 1 | 0 | No | No |
| 15014628 | CONTACT LENS DISINFECTING SYSTEM | February 2016 | August 2017 | Allow | 19 | 2 | 1 | No | No |
| 14877668 | METHOD FOR INCREASING PLANT YIELD, AND YIELD IMPROVING COMPOSITIONS | October 2015 | December 2015 | Allow | 2 | 0 | 0 | No | No |
| 14779927 | COMPOSITION FOR EXTERNAL USE PREPARATION WITH IMPROVED TRANSDERMAL PERMEABILITY | September 2015 | March 2019 | Allow | 41 | 4 | 0 | No | No |
| 14861046 | Drug Particles From Freezing Onto A Surface | September 2015 | February 2025 | Abandon | 60 | 16 | 0 | Yes | Yes |
| 14659819 | PHARMACEUTICAL COMPOSITIONS FOR EXTENDED RELEASE OF OXYCODONE AND ACETAMINOPHEN RESULTING IN A QUICK ONSET AND PROLONGED PERIOD OF ANALGESIA | March 2015 | December 2016 | Allow | 21 | 1 | 0 | No | No |
| 13979658 | Anti-microbial wound dressing and a method of producing the same | July 2014 | July 2019 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 14075536 | INJECTABLE MICROSPHERES FOR DERMAL AUGMENTATION AND TISSUE BULKING | November 2013 | November 2015 | Allow | 24 | 4 | 0 | Yes | No |
| 13961674 | INJECTABLE MICROSPHERES FOR DERMAL AUGMENTATION AND TISSUE BULKING | August 2013 | October 2013 | Allow | 2 | 0 | 0 | No | No |
| 13890523 | MICRONIZED TANAPROGET, COMPOSITIONS, AND METHODS OF PREPARING THE SAME | May 2013 | February 2014 | Allow | 10 | 1 | 0 | No | No |
| 13818307 | PROCESS FOR TREATING SOL-GEL CAPSULES | February 2013 | November 2016 | Allow | 45 | 3 | 1 | No | No |
| 13813557 | COLLAGEN-BASED IMPLANTS FOR SUSTAINED DELIVERY OF DRUGS | January 2013 | November 2015 | Allow | 33 | 1 | 0 | No | No |
| 13812497 | Growth-inhibited hydroxyapatite, process for its preparation and use | January 2013 | August 2014 | Allow | 19 | 1 | 1 | Yes | No |
| 13634135 | ENTEROBACTER SP- 638 AND METHODS OF USE THEREOF | January 2013 | January 2020 | Allow | 60 | 8 | 1 | Yes | Yes |
| 13695917 | COMPOSITIONS CONTAINING ACRYLIC THICKENER | December 2012 | April 2015 | Allow | 29 | 3 | 1 | No | No |
| 13730301 | METHOD FOR INCREASING PLANT YIELD, AND YIELD IMPROVING COMPOSITIONS | December 2012 | June 2015 | Allow | 30 | 2 | 1 | No | No |
| 13723370 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | December 2012 | May 2016 | Allow | 41 | 4 | 1 | No | No |
| 13689177 | COMPOSITIONS CONTAINING MICRONIZED TANAPROGET PREPARED BY WET GRANULATION | November 2012 | March 2014 | Allow | 16 | 0 | 1 | No | No |
| 13667296 | THERAPEUTIC FOAM | November 2012 | January 2014 | Allow | 14 | 1 | 0 | No | No |
| 13649077 | COMPOSITIONS AND METHODS FOR TREATING NEPHROPATHY | October 2012 | October 2015 | Allow | 36 | 3 | 1 | Yes | No |
| 13582901 | Emulsifiable Concentrate | October 2012 | June 2015 | Allow | 34 | 3 | 1 | Yes | No |
| 13606837 | ORAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF HUMAN CANITIES | September 2012 | March 2014 | Allow | 18 | 2 | 0 | No | No |
| 13547757 | Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated with Individuals Suffering from Alcohol Intoxication | July 2012 | June 2015 | Allow | 36 | 2 | 1 | No | No |
| 13518774 | POLYMER COMPOSITION AND MOLDED ARTICLES SHAPED OF THE SAME | June 2012 | October 2014 | Allow | 28 | 2 | 1 | No | Yes |
| 13480901 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | May 2012 | June 2015 | Allow | 37 | 3 | 1 | No | No |
| 13473586 | PHARMACEUTICAL COMPOSITIONS FOR EXTENDED RELEASE OF OXYCODONE AND ACETAMINOPHEN RESULTING IN A QUICK ONSET AND PROLONGED PERIOD OF ANALGESIA | May 2012 | December 2014 | Allow | 31 | 2 | 1 | Yes | No |
| 13429314 | COMBINATION COMPOSITION COMPRISING BENZOYL PEROXIDE AND ADAPALENE | March 2012 | June 2013 | Allow | 15 | 1 | 0 | No | No |
| 13423443 | FOSFOMYCIN PHARMACEUTICAL COMPOSITION | March 2012 | September 2013 | Allow | 18 | 1 | 0 | No | No |
| 13379691 | REFRESHING CREAM FOUNDATION IN GEL FORM | December 2011 | October 2013 | Allow | 22 | 1 | 1 | No | No |
| 13247287 | METHODS FOR PROCESSING MICROSPHERES | September 2011 | October 2013 | Allow | 24 | 1 | 1 | Yes | No |
| 13228216 | TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION | September 2011 | July 2013 | Allow | 23 | 2 | 1 | No | No |
| 13182798 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | July 2011 | August 2013 | Allow | 25 | 1 | 1 | Yes | No |
| 13125607 | TEMPLATE FOR BACTERIAL CELLULOSE IMPLANT PROCESSED WITHIN BIOREACTOR | July 2011 | May 2015 | Allow | 49 | 4 | 0 | No | No |
| 13164037 | TRANSDERMAL DRUG DELIVERY SYSTEM AND METHOD OF USING THE SAME | June 2011 | July 2014 | Allow | 37 | 2 | 0 | No | No |
| 12669907 | METHOD FOR PRODUCING MECHANICALLY ACTIVATED AMORPHOUS AND AMORPHOCRYSTALLINE COMPOUNDS OF GLUCONIC ACID CALCIUM SALT | March 2011 | July 2014 | Allow | 54 | 2 | 1 | Yes | No |
| 12987367 | IMMEDIATE RELEASE COMPOSITIONS OF ACID LABILE DRUGS | January 2011 | January 2015 | Allow | 49 | 3 | 0 | No | No |
| 12981077 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS | December 2010 | June 2014 | Allow | 42 | 2 | 0 | No | No |
| 12280327 | INHIBITION OF JAK2 AS A TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | December 2010 | November 2012 | Allow | 51 | 1 | 0 | No | No |
| 12665977 | MULTI-DAY DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES | November 2010 | December 2014 | Allow | 59 | 3 | 1 | No | No |
| 12870708 | ADJUVANT COMPRISING ALUMINUM, OLIGONUCLEOTIDE AND POLYCATION | August 2010 | February 2014 | Allow | 42 | 3 | 0 | No | No |
| 12765980 | THERAPEUTIC FOAM | April 2010 | May 2012 | Allow | 25 | 1 | 0 | Yes | No |
| 12759952 | TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS | April 2010 | August 2013 | Allow | 40 | 5 | 0 | Yes | Yes |
| 12752520 | MICRONIZED TANAPROGET, COMPOSITIONS, AND METHODS OF PREPARING THE SAME | April 2010 | January 2013 | Allow | 34 | 1 | 0 | No | No |
| 12443447 | VERMIN POISON | March 2010 | March 2014 | Allow | 59 | 2 | 1 | Yes | No |
| 12452637 | COMPOSTIONS WITH ENHANCED BIOAVAILABILITY AND FAST ACTING INHIBITOR OR GASTRIC ACID SECRETION | February 2010 | November 2014 | Allow | 58 | 3 | 1 | No | No |
| 12617520 | SOLID COSMETIC COMPOSITION FOR APPLICATION TO KERATIN FIBRES | November 2009 | November 2013 | Allow | 48 | 3 | 1 | No | No |
| 12590520 | Insect baits | November 2009 | June 2012 | Abandon | 31 | 4 | 1 | Yes | No |
| 12577600 | METHODS FOR TREATING VASOMOTOR SYMPTOMS IN CASTRATED PROSTATIC CANCER PATIENTS WITH LOW DOSE CYPROTERONE ACETATE | October 2009 | July 2012 | Allow | 33 | 2 | 0 | Yes | No |
| 12557022 | TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS | September 2009 | September 2012 | Allow | 37 | 4 | 0 | No | No |
| 12534070 | INJECTABLE MICROSPHERES FOR DERMAL AUGMENTATION AND TISSUE BULKING | July 2009 | June 2015 | Allow | 60 | 5 | 0 | Yes | No |
| 12497072 | COMPOSITIONS OF KERATIN HYDROLYSATE AND MICROBES FOR PEST CONTROL APPLICATIONS | July 2009 | April 2012 | Allow | 34 | 2 | 0 | No | Yes |
| 12418443 | PESTICIDAL COMPOSITIONS | April 2009 | April 2012 | Allow | 37 | 2 | 1 | Yes | No |
| 12440727 | TOPICAL FORMULATIONS OF TELLURIUM-CONTAINING COMPOUNDS | March 2009 | August 2015 | Allow | 60 | 4 | 0 | Yes | No |
| 12392086 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING BETA-LACTAM ANTIBIOTIC AND ION-CHELATING AGENT | February 2009 | February 2013 | Allow | 48 | 2 | 0 | No | No |
| 12086596 | USE OF POLYUNSATURATED COMPOUNDS AS WHITENING AGENTS | October 2008 | April 2013 | Allow | 58 | 4 | 0 | Yes | No |
| 12212391 | Multivitamin and Mineral Compositions for Individuals Having Renal Disease | September 2008 | August 2013 | Allow | 59 | 3 | 0 | Yes | No |
| 12220339 | OM VITAMIN FORMULA | July 2008 | March 2013 | Allow | 55 | 4 | 0 | Yes | No |
| 12135077 | BIOACTIVE IMPLANT AND METHOD OF USE | June 2008 | March 2015 | Allow | 60 | 4 | 0 | Yes | No |
| 12041188 | PHOSPHODIESTERASE 4 INHIBITORS FOR COGNITIVE AND MOTOR REHABILITATION | March 2008 | October 2016 | Allow | 60 | 4 | 1 | No | Yes |
| 12034046 | FOOD SUPPLEMENT COMPOSITION SUITABLE FOR PROMOTING IRON ABSORPTION | February 2008 | October 2011 | Allow | 44 | 1 | 0 | No | No |
| 11925283 | TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS | October 2007 | January 2014 | Allow | 60 | 3 | 1 | Yes | Yes |
| 11855205 | TREATMENT FOR HIGH PRESSURE BLEEDING | September 2007 | June 2013 | Allow | 60 | 2 | 0 | No | No |
| 11750900 | PHOSPHODIESTERASE 4 INHIBITORS FOR COGNITIVE AND MOTOR REHABILITATION | May 2007 | November 2011 | Allow | 54 | 4 | 0 | Yes | Yes |
| 11652724 | APPARATUS AND METHOD FOR PREVENTING ADHESIONS BETWEEN AN IMPLANT AND SURROUNDING TISSUES | January 2007 | August 2011 | Allow | 56 | 7 | 0 | No | No |
| 11628062 | ORAL PREPARATIONS AND PROCESS FOR PRODUCTION THEREOF | November 2006 | August 2012 | Allow | 60 | 2 | 0 | Yes | No |
| 11526240 | VAGINAL TABLETS COMPRISING MISOPROSTOL AND METHODS OF MAKING AND USING THE SAME | September 2006 | November 2011 | Allow | 60 | 4 | 0 | Yes | Yes |
| 11446125 | Percutaneous absorption-type pharmaceutical preparation | June 2006 | December 2012 | Allow | 60 | 5 | 0 | No | No |
| 11382976 | TOPICAL INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION | May 2006 | October 2011 | Allow | 60 | 4 | 0 | No | Yes |
| 11412014 | COMPOSITIONS CONTAINING MICRONIZED TANAPROGET PREPARED BY WET GRANULATION | April 2006 | August 2012 | Allow | 60 | 2 | 0 | No | No |
| 11388248 | TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS | March 2006 | June 2012 | Allow | 60 | 6 | 1 | No | Yes |
| 10706243 | METHOD FOR DRUG DELIVERY TO THE PULMONARY SYSTEM | November 2003 | December 2012 | Allow | 60 | 11 | 0 | Yes | Yes |
| 10677818 | CYTOPROTECTION BY MEANS OF PHOSPHOTYROSINE | October 2003 | November 2011 | Allow | 60 | 6 | 1 | No | Yes |
| 10635402 | TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHOD FOR THEIR PRODUCTION | August 2003 | May 2011 | Allow | 60 | 7 | 1 | No | Yes |
| 10339226 | SELECTIVE ENZYMATIC ESTERIFICATION AND SOLVOLYSIS OF EPIMERIC VITAMIN D ANALOG AND SEPARATION OF THE EPIMERS | January 2003 | October 2011 | Allow | 60 | 6 | 1 | Yes | Yes |
| 10176135 | QUICK DISSOLVE COMPOSITIONS AND TABLETS BASED THEREON | June 2002 | March 2010 | Allow | 60 | 6 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SOROUSH, ALI.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 37.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SOROUSH, ALI works in Art Unit 1614 and has examined 84 patent applications in our dataset. With an allowance rate of 92.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner SOROUSH, ALI's allowance rate of 92.9% places them in the 79% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by SOROUSH, ALI receive 3.08 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SOROUSH, ALI is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -2.4% benefit to allowance rate for applications examined by SOROUSH, ALI. This interview benefit is in the 6% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 25.6% of applications are subsequently allowed. This success rate is in the 31% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 150.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 88% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 58.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 92.9% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.